Pay in 4 interest-free payments of $5.73 Learn more
Ships within 48 hours · Estimated delivery Aug 3 - Aug 8
[DOI] [PMC free article] [PubMed] [Google Scholar] 35.Alam Q., Alam M.Z., Mushtaq G., Damanhouri G.A., Rasool M., Kamal M.A., Haque A
Cagrilintide development and structure What cagrilintide is: Synthetic long-acting amylin analog Modified 37-amino acid sequence Developed by Novo Nordisk Designed specifically for obesity treatment Based on natural amylin but optimized Key structural modifications: Amino acid substitutions for stability Prevented amyloid aggregation (major improvement) Extended half-life to ~7 days (vs minutes for natural amylin) Maintained receptor binding and activity Better pharmacokinetic profile Development timeline: Early 2010s: Initial development 2019-2020: Phase 2 trials (OASIS) 2021-2023: Phase 3 trials (REDEFINE as CagriSema) 2024-2025: FDA submission expected Likely approval 2025-2026 Why cagrilintide is breakthrough: First truly long-acting amylin agonist Weekly dosing (vs pramlintide 2-3x daily) Designed for weight loss (not diabetes adaptation) Proven synergy with semaglutide (CagriSema) Approaching availability Cagrilintide weight loss results Monotherapy clinical data (OASIS trials): Duration: 26-68 weeks Dose: 2.4mg weekly (standard) Average weight loss: 10-12% Some participants: 15%+ loss Well-tolerated at therapeutic dose Weight loss by dose: 0.6mg weekly: ~6% weight loss 1.2mg weekly: ~8% weight loss 2.4mg weekly: ~10% weight loss 4.5mg weekly: ~12% weight loss (higher side effects) CagriSema combination (cagrilintide + semaglutide): Both at 2.4mg weekly Average weight loss: 15.6% (REDEFINE-1) Excellent responders: 20-25% 50% more than semaglutide alone Game-changing results Real-world expectations: See our comprehensive cagrilintide weight loss guide
References Pizzorno, J
They lack the systemic context necessary to recapitulate inter-organ crosstalk (e.g., hepatic regulation of cardiac copper) and are inherently static, making them unsuitable for modelling the gradual pathogenesis of chronic copper imbalances
These therapies may not be appropriate for individuals who are pregnant or breastfeeding, have certain chronic medical conditions, active cancer, or known allergies to components of the injections
US$ 27.85
US$ 23.96
US$ 22.17